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Cancer is an emerging public health problem in Africa. According to the World Health Organization 
(WHO), the numbers will be doubled by 2030 because of the ageing and the growth of the population. 
Cancer prevention strategies are limited in Africa; therefore, most cancers are diagnosed at an 
advanced stage.1 A shortage of medical specialists, nurses and pathology workers contributes to a late 
presentation and low attendance in hospitals. Several new cancer registries have been established in 
Africa in the past 10 years. Prostate cancer is the most common cancer among men in most African 
countries.2 Data from Zimbabwe demonstrate the increasing trend in prostate cancer incidence 
throughout Africa.2,3 All these countries share a common ‘Westernisation’ of lifestyles among their 
urban populations, suggesting the role of environmental factors such as diet (high fish content and 
low animal fat replaced by Western diet containing high animal fat).4 Radiotherapy machines are 
extremely limited in Africa and therefore prostate cancer in Africa is mostly managed by urologists. 
However, for a large proportion of prostate cancer patients, external-beam radiotherapy (EBRT) will 
be the treatment of choice in Africa because of limitations of surgical expertise in many countries.
An important biological parameter describing the response of tissues to fractionation is the repair 
capacity (α/β ratio). Late responding tissues are characterised by a relatively low α/β ratio (3–4 
Gy), resulting in an enhanced sensitivity for large fraction doses. Acute responding healthy tissues 
and most tumours are characterised by a high α/β ratio (10 Gy) and therefore are relatively 
insensitive to large fraction doses, compared to tissues with low α/β ratio. Prostate cancer has a 
highly atypical growth pattern in comparison with other malignancies and has a low α/β ratio, 
probably even lower than late responding healthy tissues.5 The disparity between the α/β ratio for 
late complications and the low α/β ratio for prostate cancer widens the therapeutic window by 
treating prostate cancer with hypofractionation. Hypofractionated schedules for prostate cancer 
have been used for many years, but only recently several randomised clinical trials have been 
published to study the possibility of a high therapeutic gain delivering a higher biological dose to 
the prostate without increasing toxicity. The question raised here is: could this shortened schedule 
find a place in radiation delivery in resource-constrained settings? This perspective will review 
the evidence and potential utilisation of hypofractionated EBRT in Africa.
Cancer is an emerging public health problem in Africa. According to the World Health 
Organization, the numbers will be doubled by 2030 because of the ageing and the growth of 
the population. Prostate cancer is the most common cancer among men in most African 
countries. Radiotherapy machines are extremely limited in Africa and therefore prostate cancer 
in Africa is mostly managed by urologists. However, for a large proportion of prostate cancer 
patients, external-beam radiotherapy (EBRT) will be the treatment of choice in Africa because 
of limitations of surgical expertise in many countries. The disparity between the α/β ratio for 
late complications and the low α/β ratio for prostate cancer widens the therapeutic window 
when treating prostate cancer with hypofractionation. Because of the reduced number of 
treatment days, hypofractionation offers economic and logistic advantages, reducing the 
burden of the very limited radiotherapy resources in most African countries. It also increases 
patient convenience. A misleading assumption is that high-level radiotherapy is not feasible in 
low-income countries. The gold standard option for hypofractionation includes daily image-
guided radiotherapy with 3–4 implanted gold fiducials. Acceptable methods for image 
guidance include ultrasound and cone-beam computed tomography (CT). CT-based treatment 
planning with magnetic resonance imaging fusion allows for accurate volume delineation. 
Volumetric modulated arc therapy or inversely planned intensity modulated radiotherapy is 
the ideal for treatment delivery. The most vital component is safe delivery, which necessitates 
accurate quality assurance measures and on-board imaging. We will review the evidence and 
potential utilisation of hypofractionated EBRT in Africa.
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Hypofractionation trials
A variety of schedules have been tested in clinical trials 
(see Table 1). The Dutch HYPRO trial randomised 820 
intermediate- to high-risk patients to 39 fractions of 2 Gy 
(5 fractions/week) or 19 fractions of 3.4 Gy (3 fractions/
week).6 This study was designed to test whether an equivalent 
increased dose of 12.4 Gy in 2-Gy fractions using 
hypofractionated EBRT would achieve a significant increase 
in relapse-free survival (RFS) of 10% as compared to 
conventional treatment.6 At a median follow-up of 60 months, 
no significant differences in RFS were achieved with rates 
of 80% and 77% after hypofractionation and conventional 
fractionation, respectively.
The CHHiP trial randomised 3216 patients with intermediate- 
or high-risk prostate cancer to conventional fractionation of 
74 Gy in 37 fractions or two hypofractionation schedules: 
57 Gy in 19 fractions or 60 Gy in 20 fractions.7 Hypofractionated 
treatment using 60 Gy in 20 fractions was found non-inferior 
to conventional treatment with 5-year RFS rates of 88% and 
91% after conventional and hypofractionated treatment, 
respectively. The 57 Gy schedule was found to be inferior. 
The RTOG 0415 trial also demonstrated non-inferiority of 
hypofractionated EBRT of 70 Gy in 28 fractions versus 73.8 Gy 
in 41 fractions in 1115 patients with low-risk prostate cancer.8
There was significantly more acute grade ≥ 2 bowel toxicity 
during treatment in the CHHiP and the HYPRO trials; 
however, the observed differences between arms had 
dissipated after completion of treatment.6,7 In contrast to 
bowel toxicity, all trials reported comparable acute bladder 
toxicities between treatment schemes. In terms of late 
toxicity, both the RTOG 0415 and the HYPRO trials 
demonstrated increased grade ≥ 2 bowel and bladder toxicity 
with hypofractionated EBRT as compared to conventional 
treatment.6,8 In contrast, the CHHiP trial did not find any 
difference in late toxicity between the arms and the authors 
concluded that their hypofractionated regimen of 60 Gy in 
3-Gy fractions should be considered as new standard of care 
for EBRT of localised prostate cancer.7 The increase in late 
toxicity in the HYPRO trial was limited; for example, grade 
3 nocturia (≥ 6 times/night) was reported in 19% after 
hypofractionation versus 13% in the conventional arm.6 It is 
questionable whether these differences are clinically relevant. 
Patients might prefer a slightly increased toxicity risk if the 
number of hospital visits can be reduced. Very recently, 
Catton et al. reported on 1206 patients with intermediate-risk 
prostate cancer and without anti-androgen therapy (ADT), 
randomised to 39 × 2 Gy and 20 × 3 Gy.9 The hypofractionated 
regimen was not inferior to conventional radiotherapy and 
was not associated with increased late toxicity. The authors 
concluded that the hypofractionated schedule is more 
convenient for patients and therefore should be considered 
for intermediate-risk prostate cancer.9 Patient selection is 
paramount when considering hypofractionation. Those men 
with compromised urinary function at baseline were at risk 
of late bladder toxicity,6 and therefore they might not be the 
right patients to prescribe hypofractionation.
Regarding erectile functioning, the HYPRO trial showed 
no significant differences between treatment arms in 
patients who received no or short-term ADT.
Stereotactic body radiotherapy (SBRT) delivered using 
gantry-based Linacs is an example of profound 
hypofractionation, using dose fractions of 5–10 Gy. Several 
small studies, mainly phase II non-randomised studies, 
including only low-stage prostate cancer, have been recently 
published.10,11,12,13 Current clinical data provide excellent 
short-term control rates for SBRT; toxicity induced by SBRT 
at the more established fraction dose of 5–8 Gy10,12,13 does not 
appear to be substantially higher as compared to conventional 
treatments. Future randomised trials will help determine the 
efficacy and safety of SBRT.
Why consider hypofractionation 
in Africa?
Hypofractionation offers economic and logistic advantages, 
reducing the burden of the very limited radiotherapy 
resources in most African countries. It also increases patient 
convenience. A misleading assumption is that the required 
high-level radiotherapy is not feasible in low-income 
countries because of costs, lack of electricity, poor transport, 
geopolitical instability, lack of specialised staff, and education 
and training activities; however, this does not hold true in 
all countries.14 Education of technical personnel and staff 
is feasible. Ongoing quality assurance can be supported 
through web-based systems, with teleconferencing in a 
sister institution either in Europe or in the USA. Several 
studies have been performed on automated treatment plan 
generation for prostate cancer.15,16 Generally, the automatically 
generated plans are considered similar or of higher quality 
compared to plans generated with conventional trial-and-
error planning. Automated treatment planning, performed in 
collaboration with a partner institute to guarantee high plan 
quality, might be investigated. The most vital component is 
safe delivery which necessitates accurate quality assurance 
measures and on-board imaging.17
Technical requirements for 
hypofractionation
The gold standard option includes image-guided radiotherapy 
with 3–4 implanted gold fiducials. Acceptable methods for 
image guidance include ultrasound and cone-beam computed 
tomography (CT). CT-based treatment planning with 
magnetic resonance imaging fusion allows for accurate 
TABLE 1: Hypofractionated protocols.
Risk group Stage Schedule Reference
Intermediate-high risk cT1b-T4, any Gleason sum, 
PSA ≤ 60 µg/L
19 × 3.4 Gy  
3 weekly
6
Intermediate-high risk cT1b-T3a, any Gleason sum, 
PSA ≤ 30 µg/L
20 × 3 Gy  
5 weekly
7
Low risk cT1-2b, Gleason sum ≤ 6, 
PSA ≤ 10 µg/L
5 × 7 Gy  
1 weekly
10
Source: Authors’ own work
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volume delineation. Volumetric modulated arc therapy 
(VMAT) or inversely planned intensity modulated 
radiotherapy (IMRT) is the ideal for treatment delivery. 
Position verification prior to every fraction with electronic 
kilovoltage or megavoltage portal imaging or X-ray 
volumetric imaging ensures accurate delivery.
A reasonable option whether or not VMAT or IMRT techniques 
are available is modified forward planning with the field-in-
field technique, or three-dimensional conformal therapy with 
higher energies.
In resource-constrained settings, setup verification with daily 
online electronic portal imaging and bony setup correction 
remains feasible with the addition of appropriate planning 
target volumes. This is not suitable for the weekly high-dose-
per-fraction regimens but is well suited to the 19–20 fraction 
schedules and has been adopted in some centres in Africa.
Conclusions
Several randomised clinical trials have shown the efficacy 
and safety of hypofractionated EBRT for prostate cancer. 
Those men with compromised urinary function at baseline 
are at risk of late bladder toxicity; therefore, patient 
selection is paramount when considering hypofractionation. 
Hypofractionation offers economic and logistic advantages, 
reducing the burden of the very limited radiotherapy resources 
in most African countries. It also increases patient convenience. 
The most vital component is safe delivery, which necessitates 
accurate quality assurance measures and on-board imaging.
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